Articles from RapidAI

RapidAI, the gold standard and global leader in neurovascular AI-based clinical decision support and enterprise radiology solutions, today announced new study findings that underscore its continued leadership in stroke imaging. The findings emphasize that not all AI is created equal, with results showing that RapidAI’s clinically deep algorithms deliver superior accuracy in detecting medium vessel occlusions (MeVOs) compared to Viz.ai.

RapidAI, the gold standard in neurovascular AI-based clinical decision support and a leader in enterprise radiology solutions, today announced pivotal results from the most extensive real-world study to date on AI for aneurysm detection. Presented at the 2025 American Association of Neurological Surgeons (AANS) Annual Meeting, the retrospective, single-center study analyzed 11,694 consecutive CTA scans1, demonstrating how RapidAI’s clinically validated platform, Rapid Aneurysm, can enhance diagnostic confidence and consistency, particularly in detecting nuanced or hard-to-visualize intracranial anomalies such as aneurysms when used in conjunction with standard clinical interpretation.

The numbers speak for themselves, RapidAI’s deep clinical AI is delivering results where competitors are falling short. New data from the largest head-to-head study to date proves RapidAI’s LVO detection outperforms Viz.ai by a staggering 33%, detecting far more stroke cases and reducing the risk of missed diagnoses.

RapidAI, the global leader in AI-driven medical imaging analysis and coordinated care, has received FDA 510(k) clearance for Lumina 3D™ by RapidAI—an industry-first, automated 3D imaging reconstruction solution designed to replace manual workflows with an AI-powered approach based on the latest groundbreaking AI technology advances.

RapidAI, the world leader in AI-driven medical imaging analysis and coordinated care, today announced the launch of its Rapid Enterprise™ Platform, powered by Rapid Edge Cloud. Rapid Enterprise includes the addition of the Rapid Navigator Pro™ and third-party integration. Rapid Edge Cloud is the industry’s only premier hybrid platform, combining on-premise and cloud-based capabilities. This expansion sets a new standard for cross-disciplinary deep clinical AI deployment and is engineered to revolutionize workflows within health system radiology departments and beyond. The enhanced platform delivers unparalleled speed, flexibility, cybersecurity, and seamless integration capabilities.

RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and patient workflow solutions, and the Alaska Stroke Coalition (ASC) today announced their partnership on the “Rapid AK” project – a three-year initiative focused on advancing health equity for Alaskans affected by stroke. As part of the effort, six hospitals across the state have implemented RapidAI’s core stroke imaging and workflow products to help overcome challenges associated with rural care, joining an additional four Alaskan hospitals already leveraging the technology to improve stroke identification and treatment in their regions.

RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced that the Food and Drug Administration (FDA) has granted 510(k) clearance for its AngioFlow™ by RapidAI solution. The module delivers perfusion imaging analysis directly within the interventional suite to promote greater clinical confidence, workflow efficiency, and potentially improve patient outcomes.

RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM). Other select data from research studies unveiled last week at the American Heart Association’s International Stroke Conference (ISC) underscore and reinforce the pivotal role of the RapidAI platform in advancing stroke care.

RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, will showcase its clinical expertise and industry-leading innovation at the American Heart Association’s International Stroke Conference (ISC) in Phoenix, AZ, February 7-9. Through various research presentations, poster abstracts, and learning sessions, RapidAI will highlight how its AI platform is reshaping the industry and driving confident, efficient, and accessible patient care.

RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, has been named to CB Insights’ fifth-annual Digital Health 50 (formerly Digital Health 150), a list of the 50 most promising private digital health companies of 2023.

RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, is proud to announce major milestones in advancing its industry-leading deep clinical AI, including:

RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, today announced it has received FDA clearance for Rapid SDH, its AI-powered module for the detection and notification of suspected hemispheric acute and chronic subdural hematoma.

RapidAI, a global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases, is pleased to announce Texas County Memorial Hospital’s (TCMH) implementation of RapidAI’s core stroke imaging and workflow products – including Rapid ICH, LVO, CTA and CTP – as part of its ongoing commitment to enhancing the quality of stroke care for patients in rural southern Missouri.

RapidAI, a global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases, today announced $75 million in Series C funding led by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on the enterprise software, data and technology markets. The funding aims to drive platform innovation to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals.

RapidAI, the global leader in using AI to combat life-threatening vascular and neurovascular conditions and support patient workflow, announced today that its combined hemorrhagic solution — Rapid ICH and Rapid Hyperdensity — has been selected as the “Best New Imaging Solution” in the 7th annual MedTech Breakthrough Awards, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market. This year’s program attracted more than 4,000 nominations from over 17 different countries.

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid NCCT Stroke – a major addition to the RapidAI suite of non-contrast based solutions for stroke and trauma care, and the first and only FDA cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from value-based CT imaging.

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid RV/LV, the newest addition to the Rapid PE solution. The tool empowers physicians to quickly assess the ratio between the right ventricle (RV) and the left ventricle (LV), a key indicator of pulmonary embolism (PE) severity. Automating this process will enable care teams to more quickly prioritize patients and accelerate decision making.

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for the latest release of Rapid ICH — the best performing intracranial hemorrhage (ICH) triage and notification product on the market with a sensitivity of 97% and specificity of 100%.

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA clearance for Rapid Hyperdensity, the newest addition to the RapidAI platform. The tool empowers physicians to quickly assess the severity of injury in patients with acute neuro conditions such as traumatic brain injury and brain hemorrhages – allowing for better and faster patient care decisions.

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, announced today that it has received FDA 510(k) clearance for its Rapid PE Triage & Notification product for fast identification and communication of suspected central pulmonary embolism — further strengthening RapidAI’s industry-leading clinical AI platform.

RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced Amit Phadnis, former GE Officer and Chief Digital Officer of GE Healthcare, as the company’s new Chief Innovation and Technology Officer.

RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced Karim Karti, former President and CEO of GE Healthcare Imaging, as the company’s Chief Executive Officer (CEO).

RapidAI, the leader in advanced cerebrovascular imaging, today announced the expansion of RapidAI Insights, a unique analytics solution that uses Rapid® scan, treatment, and outcome data to enable hospitals and hospital systems to make more informed business decisions, reduce costs across sites, and improve patient outcomes. New and enhanced reports give a deeper understanding of patient journeys and outcomes, team workflow and communication, as well as executive purview into the comprehensive metrics of a stroke practice.

RapidAI, the leader in advanced cerebrovascular imaging, today announced it has partnered with the World Stroke Organization (WSO) and Sociedad Iberoamericana de Enfermedad Cerebrovascular (SIECV) to become the exclusive neuroimaging partner for their new Stroke Center Certification Program in Latin America. Within the cross-continent initiative, RapidAI will provide a combination of its comprehensive AI-powered Rapid® stroke imaging platform and its unique Rapid U stroke training and certification program to hospitals across Latin America.